von Bueren, A O; Bacolod, M D; Hagel, C; Heinimann, K; Fedier, A; Kordes, U; Pietsch, T; Koster, J; Grotzer, M A; Friedman, H S; Marra, G; Kool, M; Rutkowski, S (2012). Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. British Journal of Cancer, 107(8):1399-1408.
Imesch, P; Hornung, R; Fink, D; Fedier, A (2011). Cordycepin (3'-Deoxyadenosine), an Inhibitor of mRNA Polyadenylation, Suppresses Proliferation and Activates Apoptosis in Human Epithelial Endometriotic Cells in vitro. Gynecologic and Obstetric Investigation, 72(1):43-49.
Samartzis, N; Imesch, P; Dedes, K J; Samartzis, E P; Fedier, A; Fink, D; Caduff, R; Fehr, M K (2011). Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: A tissue microarray study. BMC Cancer, 11:463.
Imesch, P; Samartzis, E P; Schneider, M; Fink, D; Fedier, A (2011). Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin. Fertility and Sterility, 95(5):1579-1583.
Imesch, P; Goehrens, A; Fink, D; Fedier, A (2011). MLH1-deficient HCT116 colon tumor cells exhibit resistance to the cytostatic and cytotoxic effect of the poly(A) polymerase inhibitor cordycepin (3'-deoxyadenosine)in vitro. Oncology Letters, 3(2):441-444.
Imesch, P; Fink, D; Fedier, A (2010). Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells. Fertility and Sterility, 94(7):2838-2842.
Dedes, K J; Dedes, I; Imesch, P; von Bueren, A O; Fink, D; Fedier, A (2009). Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anti-Cancer Drugs, 20(5):321-333.
Imesch, P; Dedes, K J; Furlato, M; Fink, D; Fedier, A (2009). MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. International Journal of Oncology, 35(3):631-640.
Fedier, A. Strategies for prevention, circumvention, and reversal of drug resistance in tumor cells. 2008, University of Zurich, Faculty of Medicine.
Dedes, K J; Szucs, T D; Imesch, P; Fedier, A; Fehr, M K; Fink, D (2007). Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Annals of Oncology, 18(9):1493-1499.
Fedier, A (2003). Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Annals of Oncology, 14(6):938-945.